EORTC continues to support the appropriate treatment of adult patients with G-CSF to prevent febrile neutropenia: guideline updates

被引：1

作者：

Clayton, Julie

机构：

来源：

GABI JOURNAL-GENERICS AND BIOSIMILARS INITIATIVE JOURNAL | 2013年 / 2卷 / 01期

关键词：

Febrile neutropenia; G-CSF; leukaemia; lymphoma; myelosuppression; risk;

D O I：

10.5639/gabij.2013.0201.016

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The European Organisation for Research and Treatment of Cancer (EORTC) has updated its 2006 guideline on the use of granulocyte colony-stimulating factor (G-CSF) for the prevention of febrile neutropenia (FN), a sometimes fatal condition in which a loss of neutrophils in patients receiving chemotherapy leads to infections and fever. The guideline provides recommendations on the assessment of risk factors for FN, and the choice of G-CSF formulation.

引用

页码：47 / 48

页数：2

共 1 条

[1] 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours [J].

Aapro, M. S. ;

Bohlius, J. ;

Cameron, D. A. ;

Dal Lago, Lissandra ;

Donnelly, J. Peter ;

Kearney, N. ;

Lyman, G. H. ;

Pettengell, R. ;

Tjan-Heijnen, V. C. ;

Walewski, J. ;

Weber, Damien C. ;

Zielinski, C. .

EUROPEAN JOURNAL OF CANCER, 2011, 47 (01) :8-32

← 1 →